FDA · United States
troglitazone — FDA regulatory status
troglitazone (REZULIN) regulatory status in the United States is tracked from public FDA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: FDA approved.
Status snapshot
- Status
- FDA approved
- Brand
- REZULIN
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
- Target
- Peroxisome proliferator-activated receptor gamma
- Structured fields
- 6
Pharmacology context used for competitive intelligence: Peroxisome proliferator-activated receptor gamma agonist. Target: Peroxisome proliferator-activated receptor gamma. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — FDA: approved.
Linked evidence on this spoke: 0 published clinical programs and 2 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| FDA | United States | approved | — | Evidence |
Related patents
Related hubs
FAQ
What is the FDA approval status of troglitazone?
troglitazone currently shows FDA approved in our United States regulatory index. Confirm on the official FDA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get troglitazone regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.